Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation
Portfolio Pulse from Benzinga Newsdesk
Kiromic BioPharma's Deltacel therapy has received FDA Fast Track designation for treating metastatic non-small cell lung cancer. This designation aims to expedite the development and review process, potentially improving progression-free and overall survival for patients.

August 14, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kiromic BioPharma's Deltacel therapy has received FDA Fast Track designation, which could expedite its development and review process, potentially leading to faster market entry and improved patient outcomes.
The FDA Fast Track designation is significant as it facilitates more frequent communication with the FDA, potential priority review, and a rolling submission of applications. This can lead to faster market entry and improved patient outcomes, which is positive for Kiromic BioPharma's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100